CME Group (NASDAQ:CME - Get Free Report) had its price objective boosted by Oppenheimer from $228.00 to $245.00 in a report released on Monday, Benzinga reports. The firm currently has an "outperform" rating on the financial services provider's stock. Oppenheimer's price target would indicate a potential upside of 9.61% from the stock's current price.
A number of other brokerages also recently commented on CME. Citigroup upped their price objective on shares of CME Group from $240.00 to $250.00 and gave the stock a "buy" rating in a research report on Thursday, October 3rd. Deutsche Bank Aktiengesellschaft increased their price objective on CME Group from $193.00 to $200.00 and gave the stock a "hold" rating in a research report on Thursday, August 15th. TD Cowen assumed coverage on shares of CME Group in a research report on Thursday, September 26th. They set a "hold" rating and a $221.00 target price on the stock. Piper Sandler increased their price target on shares of CME Group from $225.00 to $240.00 and gave the company an "overweight" rating in a report on Tuesday, October 8th. Finally, Bank of America boosted their price objective on shares of CME Group from $177.00 to $180.00 and gave the stock an "underperform" rating in a report on Thursday, October 3rd. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $219.53.
View Our Latest Analysis on CME Group
Shares of NASDAQ CME traded up $1.79 during midday trading on Monday, reaching $223.51. 296,957 shares of the company were exchanged, compared to its average volume of 1,945,650. The stock has a market cap of $80.48 billion, a P/E ratio of 25.44, a PEG ratio of 7.76 and a beta of 0.55. CME Group has a 1 year low of $190.70 and a 1 year high of $226.78. The stock has a fifty day simple moving average of $214.61 and a 200 day simple moving average of $207.88. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.10.
CME Group (NASDAQ:CME - Get Free Report) last posted its quarterly earnings data on Wednesday, July 24th. The financial services provider reported $2.56 earnings per share for the quarter, topping analysts' consensus estimates of $2.53 by $0.03. The company had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.53 billion. CME Group had a return on equity of 12.82% and a net margin of 56.98%. The firm's revenue for the quarter was up 12.7% on a year-over-year basis. During the same period last year, the firm earned $2.30 EPS. On average, research analysts forecast that CME Group will post 10.04 earnings per share for the current fiscal year.
In other CME Group news, CFO Lynne Fitzpatrick sold 754 shares of the firm's stock in a transaction dated Sunday, September 15th. The shares were sold at an average price of $216.99, for a total transaction of $163,610.46. Following the sale, the chief financial officer now directly owns 13,261 shares of the company's stock, valued at $2,877,504.39. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other CME Group news, CFO Lynne Fitzpatrick sold 754 shares of the business's stock in a transaction on Sunday, September 15th. The stock was sold at an average price of $216.99, for a total value of $163,610.46. Following the completion of the transaction, the chief financial officer now directly owns 13,261 shares in the company, valued at approximately $2,877,504.39. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bryan T. Durkin sold 7,593 shares of the firm's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $214.59, for a total value of $1,629,381.87. Following the sale, the director now owns 55,607 shares in the company, valued at $11,932,706.13. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.30% of the company's stock.
Large investors have recently modified their holdings of the stock. Salomon & Ludwin LLC purchased a new position in CME Group during the first quarter worth approximately $28,000. Y.D. More Investments Ltd purchased a new position in shares of CME Group in the 2nd quarter worth $36,000. Rise Advisors LLC acquired a new position in CME Group in the first quarter valued at $41,000. Thurston Springer Miller Herd & Titak Inc. grew its position in CME Group by 62.2% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 193 shares of the financial services provider's stock valued at $43,000 after acquiring an additional 74 shares during the period. Finally, McClarren Financial Advisors Inc. raised its holdings in shares of CME Group by 66.1% in the 2nd quarter. McClarren Financial Advisors Inc. now owns 196 shares of the financial services provider's stock worth $39,000 after purchasing an additional 78 shares during the period. 87.75% of the stock is currently owned by hedge funds and other institutional investors.
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.